Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 5/20 | 0.37 |
| ▸ | PPARA | Q07869 | 5/20 | 0.37 |
| ▸ | DRD3 | P35462 | 4/20 | 0.36 |
| ▸ | DRD2 | P14416 | 3/20 | 0.36 |
| ▸ | DRD4 | P21917 | 3/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.35 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28811343 | 0.92 | PPARG (0.42) | PPARGPPARADRD3DRD2DRD4 | |
| SCHEMBL19989691 | 0.91 | — | — | |
| SCHEMBL20025239 | 0.91 | DRD2 (0.38) | PPARGPPARADRD3DRD2DRD4 | |
| SCHEMBL19989622 | 0.90 | DRD3 (0.42) | PPARGPPARADRD3DRD2DRD4 | |
| SCHEMBL19989590 | 0.89 | DRD2 (0.41) | PPARGPPARADRD3DRD2DRD4 | |
| SCHEMBL19989613 | 0.89 | DRD2 (0.40) | PPARGPPARADRD3DRD2DRD4 | |
| SCHEMBL19989692 | 0.88 | DRD3 (0.40) | PPARGPPARADRD3DRD2DRD4 | |
| SCHEMBL23734924 | 0.85 | DRD2 (0.36) | PPARGPPARADRD3DRD2DRD4 | |
| SCHEMBL19989659 | 0.85 | DRD2 (0.40) | PPARGPPARADRD3DRD2DRD4 | |
| SCHEMBL23734922 | 0.84 | DRD3 (0.39) | PPARGPPARADRD3DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3519387-B1 | TETRAHYDROPYRIDINE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | DONG A ST CO LTD (KR) | 2021-08-11 | — | — | EP | disclosed |
| EP-3519387-A1 | TETRAHYDROPYRIDINE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | Dong-A ST Co., Ltd. (KR) | 2019-08-07 | — | — | EP | disclosed |
| US-10160724-B2 | Tetrahydropyridine derivatives and their use as antibacterial agents | DONG-A ST CO., LTD. (KR) | 2018-12-25 | — | — | US | disclosed |
| WO-2018062924-A1 | TETRAHYDROPYRIDINE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | DONG-A ST CO., LTD. (KR) | 2018-04-05 | — | — | WO | disclosed |
| US-20180086709-A1 | TETRAHYDROPYRIDINE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | DONG-A ST CO., LTD. (KR) | 2018-03-29 | — | — | US | disclosed |
| US-20180086709-A1 | TETRAHYDROPYRIDINE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | DONG-A ST CO., LTD. (KR) | 2018-03-29 | — | — | US | disclosed |
| US-20180086709-A1 | TETRAHYDROPYRIDINE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | DONG-A ST CO., LTD. (KR) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086709-A1 | TETRAHYDROPYRIDINE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | GALE, UGDH, PGLS | PPARG 2632/4885PPARA 2923/4885DRD3 1596/4885 |
| US-10160724-B2 | Tetrahydropyridine derivatives and their use as antibacterial agents | GALE, UGDH, PGLS | PPARG 2632/4885PPARA 2923/4885DRD3 1596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.